Bioqube Ventures’ Post

We are excited to announce the unstealthing of Spica Therapeutics with the backing of Bioqube Ventures. Spica is pioneering novel macrophage-targeted therapeutics to address the unmet needs of patients across multiple disease areas.   Follow our page for more updates as we advance our therapies towards the clinic. Read our full press release below or visit our website for more information: www.spicatx.com #SpicaTherapeutics #biotech #lifesciences

Thoughts on this? >> Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology comes to RNA >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #productmarketing #biotech

Excited to have Arkesh Mehta, Chairman & CEO of OncoBindi, Inc., at Day 2 of the Alcor Drug Discovery Platform! Join us for a compelling presentation on the NanoBindi-Platform for accelerated Therapeutics Development. Don't miss this opportunity to explore groundbreaking advancements in drug discovery! #AlcorDrugDiscovery #NanoBindi #TherapeuticsDevelopment #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

Kesmalea is proud to welcome Rob Johnson as CEO! Fresh from leading Adrestia Therapeutics (acquired by Insmed, Inc.), Rob will take the helm as we build a pipeline of oral, CNS penetrant targeted protein degrader therapeutics. These attributes are difficult to achieve for most large degraders today, but Kesmalea's SELFTAC platform was created to transform large degraders into small molecules through a self-assembling linker technology. By combining the favorable attributes of small molecules with the versatility and power of protein degradation, our goal is to bring a new class of SELFTAC degraders to patients. Read more in our press release: https://lnkd.in/e9ieuamh #biotech #CEO #therapeutics #PROTAC

At Scilligence, our goal is to provide the scientist with a unified informatics platform that embraces multi-modal entities and supports the preclinical research process. Our integrated applications, ELN, RegMol, and Inventory, empower users to generate and track data for a plethora of entities while they progress through the Make and Test portions of the DMTA cycle. For example, users can start the Make process in ELN where complex conjugates are synthesized and characterized. Check out how the Scilligence platform is enabling Next-Gen Therapeutics Research by watching the presentation recording below: https://hubs.la/Q02vbybD0

🌟 We are proud to sponsor NCI SBIR Showcase Company Saros Therapeutics at Biotech Showcase during JPM Healthcare Week. Saros will be presenting their groundbreaking nanoparticle technology during the event. 📅 Saros Therapeutics: Presentation on Tuesday, January 14 ⏰ 11:45 AM PT 📍 Room Franciscan-B 🌐 Saros Therapeutics is revolutionizing cancer and autoimmune disease treatments with its proprietary Saros metallo-nanoparticle platform. This technology safely targets innate immune cells, offering a potent and less toxic alternative to existing formulations. Saros is paving the way for safer and more effective therapies, starting with STING activation in solid tumors. With robust efficacy data, a wide therapeutic index, scalable manufacturing, and an experienced team, the company is raising capital to complete IND filing and begin a first-in-human trial. More about the science: https://lnkd.in/gUBUWDG9 Jennifer Chadwick Matt Martin #BiotechShowcase #SarosTherapeutics #Innovation #Healthcare #CancerTherapy #Nanoparticles #Biotech #LifeSciences

We are excited to announce that Forbion portfolio company ARMGO Pharma, Inc. has rebranded as RyCarma Therapeutics, reflecting its continued leadership in ryanodine receptor (RyR) biology and its commitment to developing first-in-class small molecule therapeutics. RyCarma is advancing its lead candidate, ARM210, to target leaky RyRs and correct calcium channel dysfunction in both cardiac and skeletal muscle cells. RyCarma’s recent evolution is underscored by its strengthened leadership team, including Adam Rosenberg as Chief Executive Officer, Jonathan Alspaugh as President and Chief Strategy Officer, and Sanjay Jalota as Senior Vice President of Regulatory Affairs. This marks an exciting new chapter for RyCarma Therapeutics as it continues its mission to develop life-changing treatments for patients with critical unmet medical needs. Join us in celebrating this exciting new chapter for RyCarma as they continue their mission to transform lives through cutting-edge science. Click on the following link to read the company release: https://lnkd.in/ebigeZEp #Forbion #PortfolioCompany #RyCarma #biotech #lifesciences #HeartFailure #BiotechInnovation #Leadership #InvestingInInnovation

What is #WARFTherapeutics? John Nagel says, "There is an issue in developing therapeutics on campuses, and it's called the Valley of Death. Everyone's heard of it. Many PIs can get grants to get early-stage research done, which is usually up to identifying a target or possibly validating a pathway. But it's hard to get monies to get from that point, from a validated target out to a late-stage optimized lead. So, what WARF Therapeutics does is we bridge that gap, we identify early-stage assets on campus, and then we bring the PIs and those assets into WARF Therapeutics. And the nice thing about WARF Therapeutics is once it's funded, it's funded to the end. You don't have to keep reapplying for grants every three years. We will take it all the way out either to success or failure, but we will take it all the way to the end." "And what we'll do is, if you have a small molecule program, we'll bring it in, we'll work with you and with CROs, we will develop assays, we will run high throughput screening, and we'll do early-stage/late-stage lead optimization. Then we'll do early-stage animal studies, usually in two animal models, PK/PD tox and efficacy studies. At that point in time, we should have new IP, which we will file. And then myself and Rafael, we will take this out to biotech pharma companies and VCs and find a partner to take it maybe to phase 2b, where they will then sell it off to someone else or hopefully all the way to commercialization." #WARFFAQS To learn more about WARF, visit: https://warf.org To learn more about WARF Therapeutics, visit: https://lnkd.in/ggnniR5Z

Recently, Dr Liz Dallimore spoke with Sharewise covering a number of exciting topics relating to our business. If you missed the webinar, you can watch it here ➡️ https://hubs.la/Q02Lw_Rr0 #ARG007 #AGN #ASX #strokeawareness #clinicaltrial

Listen to some great insights from our CEO Volker Herrmann, MD!